Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | PKM | P14618 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.46 |
| ▸ | MEN1 | O00255 | 9/20 | 0.46 |
| ▸ | MAPT | P10636 | 9/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14220735 | 0.81 | POLB (0.50) | ALDH1A1PKMHSD17B10KMT2AMEN1 | |
| SCHEMBL14220736 | 0.79 | CHRNA7 (0.47) | HSD17B10KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL18878432 | 0.76 | KMT2A (0.43) | ALDH1A1PKMHSD17B10KMT2AMEN1 | |
| SCHEMBL17827821 | 0.73 | PRKDC (0.56) | PRKDCATM | |
| SCHEMBL1960058 | 0.71 | SMN1; SMN2 (0.73) | ALDH1A1PKMKMT2AMEN1MAPT | |
| SCHEMBL2318001 | 0.71 | KMT2A (0.43) | ALDH1A1PKMKMT2AMEN1MAPT | |
| SCHEMBL7283555 | 0.71 | KMT2A (0.40) | ALDH1A1PKMKMT2AMEN1MAPT | |
| SCHEMBL27838078 | 0.69 | TDP1 (0.39) | ALDH1A1MAPTMAPK1SMN1; SMN2HPGD | |
| SCHEMBL18163734 | 0.69 | PRKDC (0.49) | ALDH1A1HSD17B10KMT2AMEN1MAPT | |
| SCHEMBL26054643 | 0.69 | KMT2A (0.44) | ALDH1A1PKMKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885343-A1 | INDOLE COMPOUNDS AS EZH2 INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9419318-B2 | Method of producing photoelectric conversion element, photoelectric conversion element and photoelectrochemical cell | FUJIFILM CORPORATION (JP) | 2016-08-16 | — | — | US | disclosed |
| US-9419318-B2 | Method of producing photoelectric conversion element, photoelectric conversion element and photoelectrochemical cell | FUJIFILM CORPORATION (JP) | 2016-08-16 | — | — | US | disclosed |
| US-20120305905-A1 | METHOD OF PRODUCING PHOTOELECTRIC CONVERSION ELEMENT, PHOTOELECTRIC CONVERSION ELEMENT AND PHOTOELECTROCHEMICAL CELL | FUJIFILM CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120305905-A1 | METHOD OF PRODUCING PHOTOELECTRIC CONVERSION ELEMENT, PHOTOELECTRIC CONVERSION ELEMENT AND PHOTOELECTROCHEMICAL CELL | FUJIFILM CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-1905762-A1 | PYRAZOLONE DERIVATIVE | Genecare Research Institute Co., Ltd (JP) | 2008-04-02 | — | — | EP | disclosed |
| EP-1900728-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRAZOLONE DERIVATIVE | Genecare Research Institute Co., Ltd (JP) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | BCL6, BCL6B, EZH2 | ALDH1A1 4211/4885PKM 4276/4885HSD17B10 3519/4885 |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | ALDH1A1 2824/4885PKM 3481/4885HSD17B10 418/4885 |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BAZ2A | ALDH1A1 3052/4885PKM 2939/4885HSD17B10 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.